Five Californians Selected as Breakaway from Cancer(R) Champions to be Honored During Amgen Tour of California Read more about Five Californians Selected as Breakaway from Cancer(R) Champions to be Honored During Amgen Tour of California
Amgen to Present at the Deutsche Bank 36th Annual Healthcare Conference Read more about Amgen to Present at the Deutsche Bank 36th Annual Healthcare Conference
Amgen Outlines Strategy, Growth Objectives and Capital Allocation Plans Read more about Amgen Outlines Strategy, Growth Objectives and Capital Allocation Plans
Amgen and UCB Announce Positive Phase 2 Results of AMG 785/CDP7851 in Patients With Postmenopausal Osteoporosis (PMO) Read more about Amgen and UCB Announce Positive Phase 2 Results of AMG 785/CDP7851 in Patients With Postmenopausal Osteoporosis (PMO)
Amgen to Webcast 2011 Business Review Meeting on April 21 Read more about Amgen to Webcast 2011 Business Review Meeting on April 21
Amgen Announces Webcast of 2011 First Quarter Financial Results Read more about Amgen Announces Webcast of 2011 First Quarter Financial Results
Amgen Establishes Commercial Operations in Brazil Read more about Amgen Establishes Commercial Operations in Brazil
Amgen to Appeal CHMP Opinion on Vectibix(R) (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer in Europe Read more about Amgen to Appeal CHMP Opinion on Vectibix(R) (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer in Europe
Top-Line Results Announced of Pivotal Phase 3 Motesanib Trial in Advanced Non-Squamous Non-Small Cell Lung Cancer Patients Read more about Top-Line Results Announced of Pivotal Phase 3 Motesanib Trial in Advanced Non-Squamous Non-Small Cell Lung Cancer Patients
Prolia(R) (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial Read more about Prolia(R) (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial
